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ABSTRACT
Although high-dose chemotherapy (HDC) with stem cell rescue for the treatment of women with metastatic breast
cancer (MBC) is currently a controversial strategy, we report the long-term outcomes of women undergoing high-
dose therapy for MBC over the past 12 years while participating in a sequence of research studies transitioning
between a single to a double intensification approach. Univariate and multivariate analyses provide a framework to
understand the prognostic factors important for event-free and overall survival. Between May 1988 and April 1998,
we enrolled 188 women with MBC into 3 trials of previously reported sequential transplantation strategies. Trial I
(long induction/single transplantation) accepted 62 women in partial or complete response to an unspecified induc-
tion therapy and treated them with high-dose CTCb (cyclophosphamide, thiotepa, and carboplatin) supported by
marrow or peripheral blood progenitor cells (PBPC). Trial II (long induction/double transplantation) accepted
68 women in partial or complete response to an unspecified induction therapy, and mobilized stem cells with 2 cycles
of AF (doxorubicin and 5-fluorouracil) with granulocyte colony-stimulating factor (G-CSF). These women then
received 1 cycle of high-dose single-agent melphalan followed 3 to 5 weeks later by CTCb, each with marrow or
PBPC support. Trial III (short induction/double transplantation) enrolled 58 women prior to chemotherapy treat-
ment for metastatic disease. Induction/mobilization consisted of 2 cycles given 14 days apart of doxorubicin and
G-CSF. In contrast to trials I and II, patients with stable disease or better response to induction were eligible to pro-
ceed ahead with 2 cycles of HDC, 1 being CTCb and the other being dose escalated paclitaxel together with high-
dose melphalan (TxM). These 2 HDC regimens were administered 5 weeks apart. TxM was given first in 32 patients
and CTCb was given first in 26 patients. The median follow-up periods for trials I, II, and III were 98, 62, and
39 months from the initiation of induction chemotherapy and 92, 55, and 36 months from last high-dose therapy,
respectively. The patient characteristics upon entry into these trials were similar. Important differences were that
only those patients achieving a partial response or better to induction therapy were enrolled and analyzed for trials I
and II, but all patients were analyzed on an intent-to-treat basis for trial III, including those who did not receive
intensification. The median event-free survival (EFS) times from induction chemotherapy were 13, 19, and 27 months
for trials I, II, and III, respectively (III versus I + II, P = .0004; III versus I, P = .0005; III versus II, P = .005; II versus
I, P = .25). The median overall survival (OS) times from induction chemotherapy were 30, 29, and 57 months for tri-
als I, II, and III, respectively (III versus I + II, P = .002; III versus I, P = .003; III versus II, P = .009; II versus I, P =
.47). By multivariate Cox regression, participation in the short induction/double transplantation trial III and having
no prior adjuvant chemotherapy remained favorable prognostic factors for both EFS and OS. The presence of visceral
Biology of Blood and Marrow Transplantation 8:198-205 (2002)
© 2002 American Society for Blood and Marrow Transplantation ASBMT
A.D.E. is now with the Breast Cancer Program, University of Colorado Health Sciences
Center, Aurora, Colorado; C.W. is now with Astrazenca, Waltham, Massachusetts.
Transplantation for Metastatic Breast Cancer
199B B & M T
INTRODUCTION
Patients with metastatic breast cancer (MBC) are con-
sidered incurable with conventional therapy. Palliation may
be achieved in that combination chemotherapy regimens,
especially those containing doxorubicin and/or taxanes,
result in response rates of 50% to 80% and complete response
rates of 4% to 27% in previously untreated patients [1].
Median response duration is generally less than 1 year. For
example, in a recent randomized study reported by Sledge
et al., the median time to treatment failure was 6 months for
single-agent doxorubicin and paclitaxel and 8 months for
the combination [2]. Overall median survival times were 19
to 22 months, with estrogen receptor negativity, visceral
dominant disease, 3 or more sites of metastatic disease, and
a short disease-free interval or prior adjuvant therapy being
factors indicating poor prognosis [2]. Patients who are
receiving conventional doxorubicin-containing chemo-
therapy but meet selection criteria for candidacy for high-
dose therapy generally have a better prognosis [3-5]. In the
MD Anderson experience, albeit with a high proportion of
chemonaive and hormone receptor–positive patients, the
median progression-free and overall survival times for this
group of patients with metastatic disease were 16 and
30 months, and the 2- and 5-year progression-free survival
rates were 31% and 7%, respectively [3].
High-dose therapy with hematopoietic stem cell support
does increase complete response (CR) and near-complete
response (nCR) rates compared with response rates expected
after conventional chemotherapy alone [6]. The typical
approach to high-dose therapy has been to treat patients
with conventional-dose chemotherapy to a best response
(long induction) and then to select the patients with respon-
sive tumors for consolidation with a single cycle of high-dose
chemotherapy (HDC). With this approach, approximately
50% of women with MBC responding to induction chemo-
therapy achieve a CR and/or nCR and approximately 15%
to 20% remain in continuous CR at 5 years [7,8]. These
results are remarkably consistent across many single and
multi-institutional trials. This strategy is limited by the fact
that only 70% of patients will have a sufﬁcient response to
be candidates and that most treated patients still relapse
within 2 years. Given the acknowledged selection biases
inherent in transplantation studies, it remains a matter of
debate whether a single high-dose cycle is better than con-
ventional therapy. In trial I, we report our updated long-
term experience with this approach.
Nonetheless, the strong scientific pharmacologic basis
for dose strategies, the observed high complete response
rates, and the frequent association in cancer treatment
between the development of high rates of CR and subse-
quent development of curative therapy support further
investigation in this arena. One such direction, rendered
potentially feasible by the increasing safety of high-dose
therapy, is to deliver multiple-cycle HDC. Multiple cycles
may enhance first-order cytotoxicity, particularly for BC,
with its lower growth fraction. Moreover, more agents and
higher cumulative doses may be delivered, potentially to
overcome drug-resistant subpopulations [9-12]. In addition
to cytokinetic issues, the solid tumor microenvironment is
known to be dynamic, including features such as intermit-
tent ischemia and hypoxia that would represent transient
pharmacologic sanctuaries that may not be present with
repeated cycles of therapy. Evidence from some models of
double transplantation in mice indicates that tandem trans-
plantation is more effective than a single transplantation [8].
Both trials II and III develop the double transplantation
concept and demonstrate its feasibility.
Another concept deserving of investigation was the role
of the induction therapy, the conventional dose therapy given
to maximum response prior to high-dose therapy. Induction
therapy prior to high-dose intensiﬁcation has a number of
possible advantages. These include reduction in tumor bur-
den, reduction in stem cell contamination, and demonstration
of chemotherapy sensitivity of the tumor. Thus patients with
inadequately sensitive tumors could be spared the morbidity
of HDC. Potential disadvantages to induction therapy
include proliferation or induction of drug-resistant tumor
populations and cumulative toxicities to the host and to stem
cells. Several lines of preclinical evidence highlight the
importance of acute acquired drug resistance [10-13] and the
up-regulation of normal pathways responsive to cellular stress
and damage [14-18]. In the clinic, repeated administration of
the same agents produces most of the measurable effect by
4 cycles [19-22]. In general, 4 to 6 cycles of chemotherapy (no
more or less) maximize curative outcomes, although mainte-
nance chemotherapy is associated with increased duration of
response. Moreover, induction therapy for BC typically
achieves only a partial response, which corresponds to a
median of about 1 log of cytoreduction in the face of almost
11 logs of tumor cells in metastatic disease.
We hypothesized that chemotherapy intensiﬁcation late
in the course of treatment (eg, after a median of 4-6 cycles)
disease shortened EFS, and hormone sensitivity was of borderline significance. No substantive differences in the
characteristics of the patient populations between the 3 trials appeared to interact with outcomes. In conclusion, we
found that single transplantation in responding patients after long induction achieves a small cohort of long-term
survivors, similar to the results reported by other transplantation centers. Adding a cycle of single-agent high-dose
melphalan in this context delayed median time to relapse but did not affect long-term EFS or OS. The double trans-
plantation approach using CTCb and TxM early in the course of treatment was associated with the best EFS and
overall survival and was safe, feasible, and tolerable. Treatment duration was only 14 weeks, and this treatment
option eliminated lengthy induction chemotherapy. Although selection biases may have in part contributed to this
effect, a randomized comparison of standard therapy versus short induction/double transplantation is warranted.
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may not be as effective as early intensification. Based on
these considerations, the design of the double transplanta-
tion/short induction trial (trial III) brought the high-dose
intensifications within the first 4 cycles of chemotherapy
and explored the sequence of the 2 transplantation regimens
[8-11,23,24]. We now report the long-term outcomes of
high-dose therapy for MBC at our institutions over the last
12 years and summarize by multivariate statistical analysis
the prognostic factors that contribute to these outcomes.
METHODS
Eligibility for Protocols
Eligibility criteria for each study were described previ-
ously, but in general were similar across the trials [7,23-26].
Women with histologically documented MBC were eligible.
No active central nervous system or histologic marrow
involvement was allowed. The patients had to be physiolog-
ically under age 60 with a Zubrod performance status of 0 to
1. Prior adjuvant therapy was allowed. A disease-free inter-
val (DFI) from completion of adjuvant chemotherapy to
diagnosis of metastases or recurrence of at least 6 months
was required. Presentation with MBC was deﬁned as a DFI
of zero. No prior chemotherapy for metastatic disease was
allowed. A cumulative dose of up to 540 mg/m2 doxorubicin
prior to HDC was allowed. Required laboratory study
results included leukocytes, 3000/mL; platelets,
100,000/mL; creatinine, 1.8 mg/dL; serum glutamic-
oxaloacetic transaminase, 2.5 × normal; bilirubin, 1.5 × nor-
mal, and a cardiac ejection fraction, 50%. These studies
were conducted according to the guidelines of the Dana
Farber Cancer Institute and Beth Israel Hospital institu-
tional review boards. Written informed consent was
obtained. The schemas are provided in Table 1.
Trial I (Long Induction/Single Transplantation). In trial I
[7], women were treated with standard chemotherapies,
typically CAF (cyclophosphamide, doxorubicin, and fluo-
rouracil) or AFM (doxorubicin, ﬂuorouracil, and methotrex-
ate), to best response. If they had achieved at least a partial
response, they underwent stem cell collection (either mar-
row or chemotherapy/granulocyte-macrophage colony
stimulating factor [GM-CSF]-mobilized peripheral blood
progenitor cells [PBPC]), followed by high-dose CTCb
(cyclophosphamide 1500 mg/m2 per day × 4 days [total
dose 6000 mg/m2], thiotepa 125 mg/m2 per day × 4 days
[total dose 500 mg/m2], and carboplatin 200 mg/m2 per day
× 4 days [total dose 800 mg/m2] delivered by 96-hour con-
tinuous infusion).
Trial II (Long Induction/Double Transplantation). In trial II
[25,26], women in partial or complete response to standard
chemotherapies underwent marrow harvesting and stem cell
mobilization with 2 cycles of AF (doxorubicin and 5-fluo-
rouracil) with G-CSF. These patients then received 1 cycle
of high-dose melphalan (140-180 mg/m2) followed 3 to
5 weeks later by CTCb with marrow and PBPC support.
Trial III (Short Induction/Double Transplantation). In trial III
[23,24], women with newly diagnosed MBC who were pre-
viously untreated with chemotherapy for metastatic disease
were eligible. Induction/mobilization consisted of 2 cycles
of doxorubicin, 30 mg/m2 per day on days 1 to 3 given 14 days
apart, with G-CSF, 5 µg/kg subcutaneously on days 4 to 12.
In contrast to patients in trials I and II, patients in trial III
with stable disease or better in response to induction were
eligible to proceed with 2 cycles of HDC. HDC regimen I
was CTCb. HDC regimen II (TxM) included taxol with
dose escalation from 0 to 475 mg/m2 given by 24-hour infu-
sion on day 1 and melphalan 180 mg/m2 in 2 divided doses
given on day 3. The HDC regimens were given 5 weeks
apart. TxM was given first in 32 patients, and CTCb was
given ﬁrst in 26 patients.
Post-Intensification Therapy
Surgery or radiation therapy to accessible sites of prior
bulk disease (generally 3 sites or fewer) and/or ﬁrst-, second-,
or third-line hormonal therapy in patients with estrogen- or
progesterone-receptor–positive disease were recommended
after intensiﬁcation. In trial III, bisphosphonate therapy was
given to patients with bony metastases. Herceptin was not
available for any of these trials.
Statistical Methods
All patients entered in trials were included in the out-
come analysis. Standard response criteria were used, but with
addition of the nCR category. CR required total disappear-
ance of tumor and/or absence of tumor by surgical biopsy in
persistent abnormalities for at least 4 weeks. nCR included
VGPR (>90% reduction with persistent radiographic abnor-
malities felt to represent scar tissue), PR* (resolution of all
soft tissue disease, but with residual abnormal bone scans
with sclerotic lesions documented by radiograph or com-
puted tomography), and NMD (all metastatic sites of disease
were surgically resected or irradiated prior to induction
chemotherapy) for at least 4 weeks. Partial response (PR)
required 50% to 90% reduction of the product of perpendic-
ular diameters of all measurable lesions for at least 4 weeks.
Stable disease (SD) was deﬁned as <50% reduction or <25%
increase of the same parameters for ≥8 weeks, and disease
progression (DP) required a ≥25% increase or the appear-
ance of any new lesions. Response designations to induction
chemotherapy did not include duration requirements. Time
to failure was calculated from day on-study to the documen-
tation of progression or death from any cause. Survival was
calculated from day on-study to the documentation of death
from any cause. Time to failure and survival were estimated
Table 1. Sequence of Studies: Schemas
Study N Initial Therapy HDC No. 1 HDC No. 2 Year
I 62 AFM × 4 CTCb 1988-1991
II 68 4 cycles→AF × 2 M CTCb 1991-1994
III 32 A × 2 TxM CTCb 1994-1996
26 A × 2 CTCb TxM 1996-1998
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using the Kaplan-Meier method [27]. Conﬁdence intervals
(CIs) were constructed around the Kaplan-Meier estimates
using Greenwood’s variance formula [28]. Univariate com-
parisons of these endpoints between patient groups based on
pretransplantation characteristics, such as induction
response, were made using the log-rank test [29]. Multiple
factors were simultaneously assessed using proportional haz-
ard regression [30]. However, because of small sample sizes,
a lack of signiﬁcance has a relatively low power to exclude a
true association or vice versa.
RESULTS
Patient Characteristics
Between May 1988 and April 1998, we enrolled
188 women with MBC into 3 sequential trials of transplan-
tation strategies: trial I (62 patients), trial II (68 patients),
and trial III (58 patients). During this time frame, approxi-
mately 180 other women with MBC were enrolled into
other transplantation trials. Reasons for not enrolling
patients in trials I/II/III were related to stopping rules for
phase I/II trials, patient unwillingness to go through a
double transplantation, insurance decisions, or patients
having already begun induction chemotherapy prior to
being evaluated.
The characteristics of the patients entering each trial
are summarized in Table 2, with the exception that more
patients with estrogen receptor–positive tumors in trial III
received no prior hormone therapy prior to chemotherapy
(P = .008) than patients in trials I and II. The patient char-
acteristics upon entry into these trials are similar, as were
staging practices. Important differences in the trials were
that only those patients achieving a partial response or bet-
ter to induction therapy were enrolled and analyzed for tri-
als I and II, but all patients were analyzed on an intent-to-
treat basis for trial III, including those who did not receive
intensiﬁcation. Median patient age was 43 years (range, 27-
57 years). One hundred seventeen patients (62%) had
received prior adjuvant chemotherapy, 95 (48%) had pre-
sented with estrogen receptor– positive disease, of whom
65% had received prior hormonal therapy. The median
DFI from initial presentation to onset of metastatic disease
was 23 months (range, 0-132 months). The median number
of organs involved was 2 (range, 1-10). Sites of disease
included visceral dominant in 86 patients (46%), bone
dominant in 40 patients (21%), and soft tissue only in the
remainder of patients (30%).
Treatment
Patients in trials I, II, and III received a median of 4, 6,
and 2 cycles of induction chemotherapy, respectively (Table 3).
Only the patients with partial or better response were
included in the analysis of trials I and II. All patients,
whether they received transplants or not, were included in
the analysis of trial III. In trial III, patients had not necessar-
ily achieved maximal responses after only 2 cycles of induc-
tion therapy. Four patients (2%) died from toxicity (3 in trial
I, 1 in trial II, and none in trial III).
Response to Therapy
In trials I, II, and III, CR/nCR rates to induction ther-
apy were 42%, 56%, and 34%, respectively. Responses were
measured after 4 to 6 induction cycles in trials I and II and
after 5 weeks in trial 3. Best overall responses following
completion of HDC included CR/nCR rates of 53%, 63%,
and 76% for trials I, II, and III, respectively.
Event-Free Survival 
Event-free survival (EFS) data are summarized in Table 3
and Figure 1. The median follow-up times for trials I, II, and
III from day 1 of induction therapy were 98 months (range,
75-140 months), 62 months (range, 33-95 months), and
Table 2. Patient Characteristics by Trial*
Trial I Trial II Trial III
Single Transplantation/ Double Transplantation/ Double Transplantation/ P
Long Induction Long Induction Short Induction Trial I/II Versus III
Years of trial 1988-1991 1991-1994 1994-1998
No. of patients 62† 68† 58‡
No. of transplantation patients 62 68 54
Age, median (range), y 42 (27-57) 44 (28-55) 43 (31-55) .31
ER–/PR–, no. (%) 32 (53%) 24 (38%) 19 (33%) .10
ER+ or PR+/prior hormone therapy, no. (%) 22 (37%) 26 (41%) 20 (34%) .53
ER+ or PR+/no prior hormone therapy, no. (%) 6 (10%) 13 (21%) 19 (33%) .008
Unknown 2 5 0
DFI, median (range), mo 18 (0-120) 26 (0-126) 24 (0-132) .37
Prior (adjuvant) chemotherapy, no. (%) 40 (65%) 40 (59%) 37 (64%) .77
Prior hormone therapy, no. (%) 29 (47%) 29 (43%) 24 (41%) .65
No. of organs involved, median (range) 2 (1-5) 3 (1-6) 2 (1-10) .20
Dominant sites of disease
Visceral, no. (%) 33 (53%) 32 (47%) 25 (43%) .38
Bone, no. (%) 8 (13%) 16 (24%) 16 (28%) .15
Soft tissue, no. (%) 21 (34%) 20 (29%) 17 (29%) .76
*ER indicates estrogen receptor; PR, progesterone receptor.
†Includes only patients completing high-dose therapy, eg, CR/PR only.
‡Includes all patients who entered trial whether or not they received high-dose therapy (intent-to-treat analysis).
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39 months (range, 25-72 months), respectively, and from day 1
of last high-dose intensiﬁcation were 92, 55, and 36 months,
respectively. The median EFS times from induction chemo-
therapy were 13, 19, and 27 months for trials I, II, and III,
respectively (III versus I + II, P = .0004; III versus I, P = .0005;
III versus II, P = .005; II versus I, P = .25). The actuarial
3-year EFS rates from induction chemotherapy were 21%
(95% CI, 6%-36%), 20% (95% CI, 5%-35%), and 46%
(95% CI, 37%-55%) for trials I, II, and III, respectively. The
actuarial 5-year EFS rates from induction chemotherapy were
15% (95% CI, 0%-33%), 14% (95% CI, 0%-35%), and 46%
(95% CI, 32%-60%) for trials I, II, and III, respectively.
The characteristics of those patients remaining event
free at the time of this report are summarized in Table 4.
Survival 
Survival data are summarized in Figure 2. The median
overall survival (OS) times from induction chemotherapy
were 30, 29, and 39+ months for trials I, II, and III, respec-
tively (III versus I and II, P = .002; III versus I, P = .003; III
versus II, P = .009; II versus I, P = .47). Of the 65 patients
alive, 44 remain event free at the time of this report. The
actuarial 3-year OS rates from induction chemotherapy
were 42% (95% CI, 32%-52%), 43% (95% CI, 29%-57%),
and 66% (95% CI, 61%-71%) for trials I, II, and III,
respectively. The actuarial 5-year OS rates from induction
chemotherapy were 29% (95% CI, 17%-41%), 28% (95%
CI, 19%-37%), and 50% (95% CI, 40%-60%) for trials I,
II, and III, respectively.
Univariate and Multivariate Analysis for EFS and OS
Univariate and multivariate analysis for EFS and OS are
summarized in Table 5. Age (<45, =45), DFI (0, 6-17 months,
8 months), estrogen receptor status (positive, negative,
unknown), hormone responsiveness (negative receptors,
positive receptors/prior hormone therapy, positive recep-
tors/no prior hormone therapy), tumor grade (3 versus <3),
prior chemotherapy (yes, no), sites of disease (visceral versus
bony or soft tissue), number of organs involved (0-1 versus
2), response to induction therapy (CR versus nCR versus PR
versus <PR), and trial (I versus II versus III) were analyzed
for their association with EFS and OS.
By univariate analysis, participation in trial III, no prior
adjuvant therapy, best response to long induction therapy (tri-
als I and II only), no visceral disease, and fewer than 2 organs
involved were favorable prognostic factors for EFS. Hormone
sensitivity had borderline significance (P = .06). The same
Table 3. Response to Therapy and EFS and OS following Therapy
Trial I Trial II Trial III
Single Transplantation/ Double Transplantation/ Double Transplantation/
Characteristic Long Induction Long Induction Short Induction
No. of patients 62* 68* 58†
No. of induction cycles, median (range) 4 (3-14) 6 (4-9) 2
Response to induction, no.
CR 11 (18%) 17 (25%) 2 (3%)
nCR (VGPR/PR*/NMD) 15 (24%) 21 (31%) 18 (31%)
PR 36 (58%) 30 (44%) 23 (40%)
<PR — — 15 (26%)
Best overall response, no.
CR 16 (26%) 23 (34%) 15 (26%)
nCR (VGPR/PR*/NMD) 17 (27%)
53%
20 (29%)
63%
29 (50%)
76%
EFS and OS following therapy
Median EFS, mo‡ 8 {13} 11 {19} 24 {27}
3-year EFS, % (95% CI) 21 (6-36) 20 (5-35) 46 (37-55)
5-year EFS, % (95% CI) 15 (0-33) 14 (0-35) 46 (32-60)
Median OS, mo‡ 25 {30} 23 {29} 54 {57}
3-year OS, % (95% CI) 42 (32-52) 43 (29-57) 66 (61-71)
5-year OS, % (95% CI) 29 (17-41) 28 (19-37) 50 (40-60)
Median follow-up, mo‡ 92 {98} 55 {62} 36 {39}
Toxic death, no. (%) 3 (4.8%) 1 (1.5%) 0
*CR/PR only. 
†All patients (intent to treat analysis). 
‡From last HDC {from induction}.
Figure 1. Event-free survival of metastatic breast cancer patients.
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factors were associated with increased survival rates. Hor-
mone sensitivity reached signiﬁcance for survival (P = .04).
By multivariate Cox regression, participation in trial III
and no prior adjuvant therapy remained favorable prognostic
factors for both EFS and OS. Lack of visceral disease was also
signiﬁcant for better EFS only. Number of sites of disease and
hormone sensitivity no longer contributed independently.
DISCUSSION
We have compared the EFS and OS of women with
MBC treated with 3 sequential strategies of high-dose ther-
apy: single transplantation/long induction, double transplan-
tation/ long induction, and double transplantation/short
induction. A small cohort (15% to 20%) of women remain
progression free years after completion of the single trans-
plantation therapy (trial I). The addition of single-agent high-
dose melphalan into that framework extended the EFS and
OS slightly during the ﬁrst 2 years of follow-up, but did not
affect long-term outcomes (trial II). Because trials I and II
accepted only women in partial or better response, the total
long-term survival rate of MBC might be estimated to be
approximately 10% to 15% (approximately 70% of 15% to
20%). In contrast, the 5-year EFS rate is estimated as 46%
(95% CI, 32%-60%) in trial III in an intent-to-treat analy-
sis. The investigators are convinced that the population of
women who entered these trials were highly selected moti-
vated people but were not signiﬁcantly different in personal
or disease characteristics from one trial to the next. The
multivariate analysis conﬁrms that there were no signiﬁcant
differences in these populations to explain the substantial
differences observed in outcomes. As shown in Table 3,
lead-time bias could contribute to longer OS in the small
excess of patients (P = .008) in trial III with estrogen recep-
tor–positive tumors who had not had prior hormone ther-
apy. Because these trials were not randomized comparisons
but were sequential studies, we recognize that comparative
analyses serve to generate hypotheses and to justify the con-
duct of definitive randomized trials that can define thera-
peutic advances.
Two features differentiate trial III from trials I and II:
the addition of taxol and the use of short versus long induc-
tion. Taxol is a highly active agent against breast cancer, and
it appears to provide at most a 2% absolute EFS advantage
in locally advanced BC [31]. A single dose of taxol could
contribute to the major differences observed between trial
III and trials I and II. However, according to results with
limited statistical power, there was also no obvious relation-
ship between the taxol dose used and disease outcome,
although there was an observed dose-toxicity relationship.
More likely, the short induction and early intensiﬁcation is
the important clinical variable here [10,11,13,32].
In support of the concept of early intensification and
Table 4. Characteristics of Event-Free and/or Living Patients*
Characteristics On-Study Event-Free Alive
No. of transplantation patients 188† 44 65
Study I 62 8 11
Study II 68 9 18
Study III 58† 27 36
Age, median (range), y 43 (25-57) 43 (25-55) 44 (25-55)
Grade 3 96/121 (79%) 28/36 (78%) 39/52 (75%)
DFI, median (range), mo 24 (0-132) 23 (0-132) 23 (0-132)
DFI ≥24 months, no. (%) 93 (49%) 20 (45%) 29 (45%)
Prior (adjuvant) chemotherapy, no. (%) 117 (62%) 19 (43%) 33 (51%)
Hormone status (n = 181/42/63), no. (%)
ER–/PR– 75 (40%) 18 (43%) 28 (44%)
ER+ or PR+/prior hormone 68 (36%) 13 (31%) 19 (30%)
ER+ or PR+/no prior hormone 38 (20%) 13 (31%) 18 (29%)
No. of organs involved, median (range) 2 (1-10) 2 (1-5) 2 (1-5)
Dominant sites of disease, no. (%)
Visceral 90 (48%) 14 (32%) 22 (34%)
Bone 40 (21%) 15 (34%) 23 (35%)
Soft tissue 58 (31%) 15 (34%) 20 (31%)
*All patients analyzed on study, those event-free, and those still alive at time of analysis. Prior hormone indicates previously treated with at least
1 hormone therapy; DFI, disease-free interval from diagnosis to metastasis. 
†Four patients did not undergo transplantation.
Figure 2. Overall survival of metastatic breast cancer patients.
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the potential clinical impact of acquired acute drug resis-
tance, Peters et al. conducted a randomized trial testing
immediate versus delayed transplantation following induc-
tion therapy [32]. Patients with MBC received 4 cycles of
AFM chemotherapy. Partial responders received immediate
high-dose therapy. Nonresponders were removed from the
protocol. Of the 25% who achieved a CR, a random half
received high-dose therapy (using CBP, STAMP I
[cyclophosphamide, cisplatin, and carmustine]) and the
other half received high-dose therapy only after relapse.
Immediate transplantation doubled the median duration of
CR (8 versus 4 months). Of the relapsed patients, 50%
achieved a second CR in response to transplantation. This
second response was sufﬁcient to provide a survival advan-
tage trend over the immediate transplantation. These
results lend support to the hypothesis that induction ther-
apy induced drug resistance that reversed over time, such
that the delayed transplantation became more effective a
median of 4 months later.
Whether single-cycle high-dose therapy is more effective
than conventional-dose therapy for the treatment of MBC
responding to long induction remains controversial and
awaits the completion and maturation of randomized trials.
Two randomized trials reported have evaluated the role of
high-dose therapy in MBC as either primary therapy or as
consolidation after induction therapy [33,34]. One trial
demonstrated an improvement in both disease free and over-
all survival with the use of high-dose therapy, but the results
of this trial did not reach statistical signiﬁcance because of the
small sample size [33]. The other trial compared single-cycle
transplantation using the CTCb regimen to 18 cycles of
conventional-dose CMF (cyclophosphamide, methotrexate,
5-ﬂuorouracil) chemotherapy in patients with at least a partial
response to long induction chemotherapy and found no dif-
ferences between the 2 treatments in EFS or OS [34]. Unfor-
tunately, with only 184 evaluable and randomized patients,
this trial had limited power to detect clinically signiﬁcant and
meaningful beneﬁts. The lower than expected CR rate of 5%
following CTCb and the low randomization rate of 55% may
have contributed to poor overall outcomes. Additional larger
and better powered randomized trials of single transplanta-
tion in responding patients are underway in Canada and
Europe and will mature for analysis in several years.
In our experience, double transplantation/short induc-
tion is safe and feasible. All eligible patients completed
both cycles of transplantation without treatment-related
mortality or need for intensive care. Approximately 20%
of patients managed their melphalan and taxol cycle
entirely as outpatients. Treatment could be delivered
within 14 to 16 weeks. The morbidity was sufficiently low
to allow this regimen to be a framework upon which to
build. Future directions include phase I efforts to add
additional new agents to the transplantation regimens
themselves (such as gemcitabine, temozolamide, and oxic
agents) and immune therapeutic approaches in the peri-
transplantation period [35].
Given the very favorable outcomes observed for patients
with MBC absent treatment-related mortality, we believe
the double transplantation/short induction regimen is ready
for randomized comparison to standard therapies. Thus we
have proposed a randomized comparison of this short
induction/double transplantation regimen to standard ther-
apy in patients with locally advanced BC in the cooperative
group setting.
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Table 5. Univariate and Multivariate Analysis of Prognostic Factors*
EFS OS
Hazard Ratio P Hazard Ratio P
Univariate Analysis
Regimen
Double transplantation/short induction versus other (trial III versus I/II) 2.09 .0004 2.06 .002
Double/short versus double/long (trial III versus II) 1.91 .005 1.97 .009
Double/long versus single (trial II versus I) 1.25 .25 1.16 .47
Adjuvant chemotherapy (none versus some) 1.87 .0005 1.66 .009
No. cycles adjuvant chemotherapy ≤ 4 versus >4) 1.6 .006 1.36 .09
Soft tissue/bone versus visceral sites 1.67 .003 1.63 .007
No. organs (0-1 versus ≥ 2) 1.45 .05 1.84 .004
Response to long induction (CR/nCR versus other) 1.77 .003 1.46 .07
Response to short induction (CR/nCR versus other) 1.65 .26 3.83 .03
Hormone sensitivity (not treated & + versus ER– or treated) 1.52 .06 1.64 .04
Multivariate Analysis
Regimen
Double/Short Induction versus other (trial III versus I/II) .0008 .02
Adjuvant chemotherapy (none versus some) .0001 .02
Soft tissue/bone versus visceral sites .004 .39
No. of organs (0-1 versus ≥ 2) .35 .10
Hormone sensitivity (not treated & + versus ER– or treated) .49 .24
DFI (0 versus other) .37 .74
*Favorable factors are listed ﬁrst.
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